Effects of growth hormone-releasing factor(1–44) on growth hormone release from human somatotrophinomas in vitro: interaction with somatostatin, dopamine, vasoactive intestinal peptide and cycloheximide

in Journal of Endocrinology
Authors:
M. C. White
Search for other papers by M. C. White in
Current site
Google Scholar
PubMed
Close
,
M. Daniels
Search for other papers by M. Daniels in
Current site
Google Scholar
PubMed
Close
,
P. Kendall-Taylor
Search for other papers by P. Kendall-Taylor in
Current site
Google Scholar
PubMed
Close
,
S. J. Turner
Search for other papers by S. J. Turner in
Current site
Google Scholar
PubMed
Close
,
D. Mathias
Search for other papers by D. Mathias in
Current site
Google Scholar
PubMed
Close
, and
G. Teasdale
Search for other papers by G. Teasdale in
Current site
Google Scholar
PubMed
Close
Restricted access
Rent on DeepDyve

Sign up for journal news

ABSTRACT

The effect of GH-releasing factor(1–44) (GRF) alone, or together with somatostatin (SRIF), dopamine (DA), vasoactive intestinal peptide (VIP) or cycloheximide was studied in a total of ten human somatotrophinomas using a static cell culture system. Growth hormone-releasing factor (2·0×10−8 mol/l) significantly (P<0·05) stimulated GH release from nine out of ten tumours over 4-h incubations, and a dose-related effect (2·0×10−10−2·0×10−8 mol/l) was observed in five tumours thus studied.

Repeated GRF (2·0×10−8 mol/l)-mediated GH release was seen during 96% (n = 25) of experiments performed on six tumours over 4 h and up to 27 days in culture. Growth hormone-releasing factor (2·0×10−8 mol/l) also stimulated GH release from five out of seven somatotrophinomas during 60-min incubations.

Somatostatin (6·1×10−9 mol/l) completely inhibited GRF-induced GH secretion from four tumours studied over 4 h, but in each case there was significant (P<0·05) 'rebound' of GH release from cultures exposed to both GRF and SRIF during a subsequent recovery period. Dopamine suppressed basal GH release from two out of four tumours, but in each case had a greater inhibitory effect on GRF-mediated GH release. Vasoactive intestinal peptide directly stimulated GH release from two out of three tumours, and the effects were additive to maximal stimulatory doses of GRF. Cycloheximide significantly (P< 0·01) enhanced GRF-stimulated release of GH during a 60-min incubation, but inhibited both basal and GRF-stimulated release over 4 and 8 h. We conclude that a static cell culture system can be used successfully to study the action of GRF on human somatotrophinoma tissue for up to 27 days in culture. Human somatotrophinomas seem to be only rarely unresponsive to the stimulatory action of GRF, which is itself significantly modulated by SRIF, DA and VIP. De-novo protein synthesis appears to be necessary for the full expression of GRF activity on human somatotrophinoma tissue.

J. Endocr. (1985) 105, 269–276

 

  • Collapse
  • Expand